Analysts' ratings for Regenxbio RGNX over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 4 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 4 | 2 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $38.22, a high estimate of $55.00, and a low estimate of $21.00. This current average has increased by 1.25% from the previous average price target of $37.75.
Deciphering Analyst Ratings: An In-Depth Analysis
In examining recent analyst actions, we gain insights into how financial experts perceive Regenxbio. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Annabel Samimy | Stifel | Maintains | Buy | $40.00 | - |
| Yi Chen | HC Wainwright & Co. | Announces | Buy | $36.00 | - |
| Luca Issi | RBC Capital | Raises | Outperform | $35.00 | $20.00 |
| Daniil Gataulin | Chardan Capital | Maintains | Buy | $52.00 | $52.00 |
| Gena Wang | Barclays | Raises | Overweight | $55.00 | $45.00 |
| Brian Skorney | Baird | Raises | Outperform | $39.00 | $34.00 |
| Andreas Argyrides | Wedbush | Maintains | Neutral | $21.00 | - |
| Dane Leone | Raymond James | Announces | Outperform | $45.00 | - |
| Andreas Argyrides | Wedbush | Maintains | Neutral | $21.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Regenxbio. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regenxbio compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Regenxbio's stock. This examination reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Regenxbio's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Regenxbio analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Regenxbio
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Regenxbio: A Financial Overview
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining Regenxbio's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -29.13% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -283.12%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Regenxbio's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -18.64%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Regenxbio's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.41%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.29, Regenxbio faces challenges in effectively managing its debt levels, indicating potential financial strain.
Understanding the Relevance of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
